By Pushkala Aripaka, Bhanvi Satija and Maggie Fick LONDON, Feb 10 (Reuters) - AstraZeneca forecast steady profit growth in ...

AstraZeneca has reported a robust rise in revenue in 2025, driven by strong demand for its cancer medicines, and struck an ...

China's Innovent Biologics has struck a new deal with Eli Lilly to develop immunology and oncology drugs, under which the U.S ...

An experimental drug combination was able to effectively treat pancreatic cancer in mouse models without tumor resistance.

Oxybutynin, a common drug to manage overactive bladder, may help alleviate hot flash symptoms among men receiving androgen ...

AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control ...

AstraZeneca has reported a strong set of fourth-quarter results and predicted a similarly strong performance for 2026, as it ...

In 2026, an estimated 67,530 people will be diagnosed with pancreatic cancer, according to the American Cancer Society. But ...

British pharmaceutical giant AstraZeneca said Tuesday that its net profit jumped 45 percent last year on strong sales of cancer drugs, as it expands its reach in the United States and China. - China, ...

Shares edged 1% higher in morning trading on Tuesday, with the stock having risen 28% in the past six months.

Nova Scotia will be the first site in the world to test a potentially groundbreaking cancer treatment. Global pharmaceutical ...